PEG-MGF (PEGylated Mechano Growth Factor) is a modified form of the MGF splice variant of insulin-like growth factor 1 (IGF-1). MGF — also known as IGF-1Ec in humans — is produced naturally when muscle tissue is subjected to mechanical stress or damage, acting as a local repair signal distinct from systemic IGF-1.[1]

The PEGylated version attaches a polyethylene glycol (PEG) chain to the native MGF peptide, extending its biological half-life from minutes to hours. This modification was developed to address a key limitation of native MGF research: its extremely rapid degradation in biological fluids, which made studying its effects in vivo technically challenging.[2]

Compound Profile

What Does PEG-MGF Actually Do?

The mechano growth factor peptide functions as a local tissue repair signal. When muscle fibres experience mechanical loading or damage, the IGF-1 gene undergoes alternative splicing to produce MGF rather than systemic IGF-1. This local MGF expression activates satellite cells — the resident stem cells of skeletal muscle — prompting their proliferation and subsequent fusion with damaged muscle fibres.[1][3]

Research suggests MGF acts primarily in the initial phase of muscle repair, activating quiescent satellite cells before systemic IGF-1 takes over to drive differentiation and maturation. The PEG-MGF form allows researchers to study these effects with extended exposure windows that native MGF’s short half-life does not permit.[2]

How PEG-MGF Works

MGF’s mechanism centres on satellite cell activation through pathways distinct from those used by mature IGF-1. While both derive from the same gene, MGF’s unique Ec domain peptide sequence enables it to activate satellite cell proliferation without simultaneously driving differentiation — a distinction that has important implications for tissue repair sequencing.[1]

At the molecular level, MGF has been shown to signal through pathways including ERK1/2 MAPK and the Fyn-RhoA-YAP axis. Recent research demonstrated that MGF regulates periodontal ligament stem cell proliferation and differentiation through this Fyn-RhoA-YAP signalling cascade, suggesting its repair-promoting effects may extend beyond skeletal muscle.[4]

The PEGylation modification does not alter MGF’s receptor binding or signalling mechanisms. Instead, the PEG chain sterically shields the peptide from enzymatic degradation, extending its functional half-life without changing its biological activity profile.

Muscle Growth Context

PEG-MGF research is most directly relevant to muscle growth contexts, given MGF’s physiological role as the mechanically activated splice variant of IGF-1. The peptide’s primary function — satellite cell activation following mechanical stress — is the initial step in the muscle repair and hypertrophy cascade.[1]

In vitro studies have demonstrated that MGF increases myoblast proliferation rates and delays differentiation, expanding the pool of satellite cells available for muscle repair. This contrasts with mature IGF-1, which primarily drives differentiation of already-activated satellite cells. The sequential model suggests MGF acts first (proliferation) and IGF-1 acts second (differentiation).[3]

In vivo evidence is more limited. Animal studies have shown MGF expression increases following resistance exercise and correlates with subsequent muscle adaptation. However, direct evidence that exogenous PEG-MGF administration enhances muscle hypertrophy beyond normal training responses is lacking. Compare with IGF-1 LR3 and Follistatin for related muscle-focused peptide profiles, or see the Muscle Growth goal page.

Recovery & Sleep Context

MGF’s role as a damage-responsive peptide connects it to recovery research. The physiological trigger for MGF production — mechanical tissue stress — means it is inherently linked to repair processes following exercise or injury.[1]

Preclinical evidence suggests MGF may accelerate tissue repair timelines. Studies in neural tissue have demonstrated that IGF-1 and MGF promote neural stem cell activation and proliferation under conditions of hypoxia-ischaemia, inflammation, and oxidative stress, indicating repair-promoting activity beyond skeletal muscle.[5] In chondrocytes, MGF pretreatment attenuated osteoarthritis progression in animal models.[6]

Direct evidence linking PEG-MGF to recovery outcomes such as reduced muscle soreness, faster functional recovery, or improved sleep quality is absent. The recovery context is inferred from MGF’s role in tissue repair biology rather than demonstrated in recovery-specific endpoints. See the Recovery & Sleep goal page for broader context.

Injury & Tissue Support Context

The injury and tissue support research context is arguably the most physiologically aligned with MGF’s endogenous function. MGF is specifically upregulated in response to tissue damage, making it a natural component of the injury response cascade.[1]

Research in neuroprotection has shown MGF interacts with nucleolin to protect against cisplatin-induced neurotoxicity, demonstrating tissue-protective effects outside the musculoskeletal system.[7] Surface-modified electrospun fibres releasing MGF have been investigated for mitigating foreign-body reactions in biomedical implant contexts, suggesting potential applications in tissue engineering.[8]

The breadth of tissues responding to MGF — skeletal muscle, neural tissue, cartilage, periodontal ligament — suggests a more generalised role in tissue repair than initially understood. However, most of this evidence comes from cell culture and small animal studies. Compare with BPC-157 and TB-500 for related tissue repair peptide research, or see the Injury & Tissue Support goal page.

PEG-MGF Benefits

• Satellite cell activation: Research demonstrates MGF selectively activates quiescent satellite cells, expanding the available pool for muscle repair — a mechanism distinct from mature IGF-1.[1][3]
• Extended half-life: PEGylation extends biological activity from minutes to hours, enabling research protocols that native MGF’s rapid degradation would not permit.[2]
• Multi-tissue repair potential: Preclinical studies show MGF-mediated repair effects in skeletal muscle, neural tissue, cartilage, and periodontal ligament.[4][5][6]
• Neuroprotective properties: MGF has demonstrated protection against chemotherapy-induced neurotoxicity in preclinical models.[7]
• Distinct from systemic IGF-1: MGF acts locally at sites of tissue damage rather than systemically, potentially offering more targeted tissue effects.[1]

PEG-MGF Side Effects

Formal safety studies of PEG-MGF in humans have not been conducted. Side effect data is limited to preclinical observations and theoretical concerns:

• Injection site reactions: As with other PEGylated peptides, local injection site reactions are a theoretical concern, though not specifically documented for PEG-MGF.
• IGF-1 pathway concerns: As a derivative of the IGF-1 system, theoretical concerns about pro-proliferative effects on pre-existing pathological cells exist, though no evidence supports this risk specifically for MGF.
• PEG immunogenicity: Repeated exposure to PEGylated compounds can generate anti-PEG antibodies in some individuals, potentially reducing efficacy over time.
• No long-term data: The absence of chronic exposure studies means long-term safety implications remain entirely unknown.

Half-Life

Native MGF has an extremely short half-life — estimated at less than 10 minutes in plasma — due to rapid enzymatic degradation. This characteristic reflects MGF’s physiological role as a local, paracrine signal that acts at the site of tissue damage rather than systemically.[2]

PEGylation extends the functional half-life to several hours, though exact pharmacokinetic parameters vary depending on PEG chain size and study conditions. The extended half-life was the primary motivation for developing PEG-MGF as a research tool, allowing investigation of MGF biology at sustained exposure levels.

Limits of Current Evidence

• No human clinical data: PEG-MGF has not been tested in human clinical trials for any indication. All evidence derives from cell culture and animal models.
• Purity and characterisation concerns: As a research peptide without pharmaceutical development, batch-to-batch consistency and purity standardisation remain uncontrolled.
• Distinction from native MGF unclear: Whether PEGylated MGF replicates the spatial and temporal dynamics of endogenous MGF expression remains debated.
• Anti-doping context: MGF and PEG-MGF are on the World Anti-Doping Agency prohibited list, which has influenced the direction and publication of research.
• Limited dose-response data: Optimal concentrations for biological effects have not been systematically established.

Verdict

PEG-MGF represents an intellectually compelling research peptide — a stabilised form of the body’s own mechanically triggered repair signal. The underlying biology of MGF as a satellite cell activator is well-established and physiologically important. PEGylation solved a genuine technical problem by extending the peptide’s otherwise impractically short half-life.

However, the translational gap between MGF biology and PEG-MGF as a therapeutic tool remains wide. No human data exists, dose-response relationships are poorly defined, and the assumption that sustained exogenous exposure replicates the brief, localised endogenous signal may be flawed. The evidence base supports PEG-MGF as a useful research tool for studying growth factor biology, but confidence in its practical application should remain proportional to the predominantly preclinical data available.

FAQ

What is PEG-MGF peptide?

PEG-MGF is a PEGylated form of Mechano Growth Factor, an IGF-1 splice variant produced naturally when muscle tissue is mechanically stressed or damaged. The PEG modification extends the peptide’s otherwise very short half-life from minutes to hours, enabling research studies of its biological effects.

What is the difference between MGF and PEG-MGF?

Native MGF has a half-life of less than 10 minutes due to rapid enzymatic degradation. PEG-MGF attaches a polyethylene glycol chain to the peptide, extending its functional duration to several hours without altering its biological mechanism of action. PEG-MGF was developed primarily as a research tool.

What is mechano growth factor?

Mechano growth factor (MGF) is an alternative splice variant of the IGF-1 gene, also known as IGF-1Ec in humans. It is produced locally in muscle tissue in response to mechanical loading or damage and activates satellite cells — the stem cells responsible for muscle repair and regeneration.

How does PEG-MGF differ from IGF-1 LR3?

Both are modified forms of IGF-1, but they represent different variants. IGF-1 LR3 is a long-acting version of mature, systemic IGF-1 that drives cell differentiation. PEG-MGF is a stabilised version of the locally produced splice variant that activates satellite cell proliferation. They act at different stages of the tissue repair process.

Is PEG-MGF the same as IGF-1?

No. While MGF derives from the same gene as IGF-1, it is a distinct splice variant with a different peptide sequence (the Ec domain) and different biological activity. MGF activates satellite cell proliferation, while mature IGF-1 primarily drives differentiation. PEG-MGF is a further modification with an added PEG chain for stability.

Has PEG-MGF been tested in humans?

No human clinical trials of PEG-MGF have been conducted. All research data derives from cell culture studies and animal models. The peptide remains an investigational research compound with no approved clinical applications.

References

1. Kasprzak A. Role of Alternatively Spliced Messenger RNA (mRNA) Isoforms of the Insulin-Like Growth Factor 1 (IGF1) in Selected Human Tumors. Int J Mol Sci. 2020. PMID: 32977489
2. Cox HD, et al. Detection of insulin analogues and large peptides >2 kDa in urine. Drug Test Anal. 2022. PMID: 35261185
3. Liu Y, et al. The role of mechano growth factor in chondrocytes and cartilage defects: a concise review. Acta Biochim Biophys Sin. 2023. PMID: 37171185
4. Feng F, et al. Mechano-growth factor regulates periodontal ligament stem cell proliferation and differentiation through Fyn-RhoA-YAP signalling. Biochem Biophys Res Commun. 2024. PMID: 39067248
5. Sha Y, et al. The Roles of IGF-1 and MGF on Nerve Regeneration under Hypoxia-Ischemia, Inflammation, Oxidative Stress, and Physical Trauma. Curr Protein Pept Sci. 2023. PMID: 36503467
6. Sha Y, et al. Pretreatment with mechano growth factor E peptide attenuates osteoarthritis. Int Immunopharmacol. 2021. PMID: 34015701
7. Podratz JL, et al. Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity. Exp Neurol. 2020. PMID: 32511954
8. Song Y, et al. Surface modification of electrospun fibers with mechano-growth factor for mitigating the foreign-body reaction. Bioact Mater. 2021. PMID: 33732968

IGF-1 DES — formally known as des(1-3) IGF-1 — is a naturally occurring truncated form of insulin-like growth factor 1 (IGF-1). This IGF-1 DES peptide consists of 67 amino acids, missing the first three N-terminal residues (glycine, proline, and glutamic acid) that are present in the full-length 70-amino-acid IGF-1 molecule.

Originally identified in bovine colostrum and human brain tissue, des(1-3) IGF-1 has attracted significant research interest due to one critical property: it exhibits approximately 10-fold greater biological potency than full-length IGF-1 in many in vitro assays. This enhanced activity stems not from stronger receptor binding but from its dramatically reduced affinity for IGF binding proteins (IGFBPs), which normally sequester over 95% of circulating IGF-1 and limit its bioavailability.

The IGF-1 DES peptide is now widely used in cell culture as a growth supplement, and has become a focal point of muscle and performance research due to its potent mitogenic and anabolic signalling properties. However, its very short half-life of approximately 20–30 minutes — far shorter than other IGF-1 variants — and the absence of clinical trials present important limitations.

Compound Profile

Structure & Relationship to IGF-1

Full-length IGF-1 is a 70-amino-acid polypeptide with structural homology to insulin. It features four domains (B, C, A, and D) connected by disulfide bonds that maintain its three-dimensional conformation. The N-terminal tripeptide Gly-Pro-Glu (residues 1–3) sits within the B domain and plays a key role in the interaction between IGF-1 and its family of six binding proteins (IGFBP-1 through IGFBP-6).

IGF-1 DES — sometimes written as igf des 1-3 — lacks this tripeptide entirely. The truncation is a naturally occurring post-translational modification: proteolytic cleavage in tissues such as the brain produces des(1-3) IGF-1 as an endogenous variant. This is not an artificial construct but a physiological form of the growth factor, though it can also be produced synthetically for research purposes.

Despite the loss of three residues, the core structure of this truncated IGF-1 remains intact. The disulfide bonds, receptor-binding surfaces, and overall tertiary fold are preserved, meaning des(1-3) IGF-1 retains full capacity to bind and activate the IGF-1 receptor (IGF-1R). What changes is its relationship with the binding proteins — a difference with profound functional consequences.

Mechanism of Action

The mechanism of action of IGF-1 DES centres on two interrelated properties: evasion of IGF binding proteins and direct activation of the IGF-1 receptor.

IGFBP Evasion

Under normal physiological conditions, more than 95% of circulating IGF-1 is bound to IGFBPs, particularly IGFBP-3 in complex with the acid-labile subunit (ALS). These binding proteins serve as a reservoir and transport system, but they also limit the amount of free IGF-1 available to interact with receptors at the tissue level.

Research demonstrates that des(1-3) IGF-1 has markedly reduced affinity for all six IGFBPs. Studies using vascular smooth muscle cells showed that local IGF-binding proteins significantly attenuated the effects of native IGF-1, while des(1-3) IGF-1 bypassed this regulatory mechanism entirely, producing substantially greater cellular responses at equivalent concentrations. This IGFBP evasion is the primary reason IGF-1 DES exhibits approximately 10-fold higher potency in cell-based assays compared to full-length IGF-1.

IGF-1R Activation

Once free from IGFBP sequestration, des(1-3) IGF-1 binds the IGF-1 receptor with comparable affinity to native IGF-1. Receptor activation triggers the canonical signalling cascade: autophosphorylation of the receptor tyrosine kinase, recruitment of insulin receptor substrates (IRS-1/IRS-2), and downstream activation of both the PI3K/Akt and MAPK/ERK pathways. These pathways drive protein synthesis, cell proliferation, differentiation, and anti-apoptotic signalling — effects relevant to both muscle and performance and recovery and repair.

Anabolic & Muscle Research

The anabolic potential of IGF-1 DES has been explored primarily through in vitro and animal models. Research into IGF-1 DES bodybuilding applications remains at the preclinical stage, but the available data offers several noteworthy findings.

Cell culture studies using porcine embryonic muscle cells demonstrated that des(1-3) IGF-1 produced significant effects on IGFBP-3 levels and promoted cellular proliferation more effectively than equimolar concentrations of native IGF-1. The truncated variant’s ability to bypass locally produced binding proteins appears to give it a distinct advantage in stimulating myoblast activity.

Research using skeletal myoblast cultures has shown that IGF-I signalling through the PI3K pathway is essential for myogenesis — the formation of new muscle fibres. When IGFBP-4 was overexpressed to sequester IGF-1 in the culture environment, muscle differentiation was substantially impaired. Des(1-3) IGF-1 was able to rescue this effect, confirming that its reduced IGFBP binding allows it to reach the IGF-1 receptor more efficiently than full-length IGF-1.

More recent work examining porcine myotubes showed that des(1-3) IGF-1 was among the most potent anabolic agents tested for stimulating myosin heavy chain (MYH4) expression — a marker of fast-twitch muscle fibre protein synthesis. These findings are consistent with the compound’s established role as a potent activator of downstream anabolic signalling, though it should be noted that cell culture conditions differ substantially from whole-organism physiology.

Compared to other peptides studied for muscle and performance, such as IGF-1 LR3 or growth hormone secretagogues like GHRP-6, IGF-1 DES offers a more direct mechanism of IGF-1R activation but with a much shorter duration of action.

Recovery & Wound Healing Evidence

The IGF-1 DES benefits observed in recovery research stem from the same IGFBP-evasion mechanism that drives its anabolic effects. By reaching the IGF-1 receptor more readily, des(1-3) IGF-1 can trigger tissue repair signalling with greater potency than the native growth factor.

A landmark study published in the Journal of Clinical Investigation examined the interaction between IGF-I family members and integrin receptors in dermal wound healing using a rabbit ear ulcer model. The research demonstrated that IGF-1, particularly when freed from binding protein sequestration, promoted fibroblast migration and collagen deposition in wound tissue. Des(1-3) IGF-1 was used as a tool compound in these experiments specifically because its IGFBP independence made it ideal for studying direct IGF-1R-mediated repair mechanisms.

Additional wound healing research confirmed that IGF-1 and IGFBP-1 together promoted fibroblast-embedded collagen gel contraction — a model of wound closure. Des(1-3) IGF-1 produced comparable effects without requiring the binding protein co-factor, further illustrating its enhanced bioavailability at the tissue level.

These preclinical findings position IGF-1 DES alongside other recovery-focused compounds such as BPC-157 and TB-500, though the evidence base for des(1-3) IGF-1 in recovery and repair remains more limited and is confined to animal and cell-based models.

Metabolic Effects

IGF-1 DES research has touched on several metabolic pathways beyond muscle growth and recovery. As an activator of IGF-1R, des(1-3) IGF-1 engages the PI3K/Akt signalling cascade, which is intimately connected to glucose metabolism, lipid handling, and cellular energy balance.

IGF-1 itself has well-documented insulin-sensitising properties — it can lower blood glucose by activating glucose transporters through pathways that partially overlap with insulin signalling. Because des(1-3) IGF-1 activates the same receptor with greater effective potency, preclinical evidence suggests it may produce more pronounced metabolic effects per unit concentration. However, this also raises the risk of hypoglycaemia, which is discussed in the safety section below.

The metabolic relevance of IGF-1 DES to fat loss and body recomposition is largely theoretical at this stage. While IGF-1R signalling is known to influence adipocyte differentiation and lipid metabolism, no studies have directly examined des(1-3) IGF-1 for body composition outcomes. Compounds with more direct evidence in this area include Fragment 176-191 and AOD-9604.

Safety & Side Effects

The IGF-1 DES side effects profile is informed by its mechanism of action rather than clinical trial data, as no human clinical trials have been conducted with this compound. Key safety considerations include:

Mitogenic Concerns

IGF-1R activation is inherently mitogenic — it promotes cell division. This is the basis for the compound’s anabolic effects, but it also means that des(1-3) IGF-1 could theoretically promote the growth of pre-existing tumours. Research has confirmed that des(1-3) IGF-1 stimulates proliferation in various cell lines, including cancer cell models. The compound’s enhanced potency relative to native IGF-1 makes this concern more pronounced. WADA (the World Anti-Doping Agency) has classified IGF-1 variants including des(1-3) IGF-1 as prohibited substances, and anti-doping laboratories have developed detection methods using immunopurification and high-resolution mass spectrometry.

Hypoglycaemia Risk

As with all IGF-1R agonists, des(1-3) IGF-1 carries the potential for blood sugar reduction. The enhanced bioavailability of this truncated variant compared to native IGF-1 may amplify this risk, though the very short half-life (~20–30 minutes) provides a degree of natural limitation.

Limited Safety Data

Perhaps the most significant IGF-1 DES side effect concern is the absence of systematic safety evaluation. Without controlled human studies, the full side effect profile, potential drug interactions, and long-term consequences remain unknown. This uncertainty applies to all IGF-1 derivatives but is particularly relevant for des(1-3) IGF-1 given its enhanced potency.

Research Limitations

While the available IGF-1 DES research is compelling at the preclinical level, several significant limitations must be acknowledged:

• No clinical trials: There are no published human clinical trials examining des(1-3) IGF-1 for any indication. All efficacy and safety data comes from cell culture experiments and animal models.
• Cell culture bias: Much of the potency data (including the ~10x figure) derives from in vitro assays where des(1-3) IGF-1 is compared against native IGF-1 in the presence of locally produced IGFBPs. In vivo conditions are substantially more complex.
• Short half-life challenges: The ~20–30 minute half-life, while well-characterised, creates practical challenges for translating cell culture findings into whole-organism effects.
• Limited number of studies: Relative to full-length IGF-1 (which has thousands of publications), the specific literature on des(1-3) IGF-1 is comparatively small.
• Oncogenic uncertainty: The long-term effects of potent IGF-1R activation on tumour risk are not well-understood for this specific variant, though the broader IGF-1/cancer literature raises legitimate concerns.

These limitations do not invalidate the research but place it firmly in the preclinical category. Researchers working with des(1-3) IGF-1 should interpret findings within this context, and comparisons with better-studied compounds like sermorelin or GHRP-2 — which stimulate endogenous growth hormone and IGF-1 through the hypothalamic-pituitary axis — highlight the difference in evidence maturity.

Verdict

IGF-1 DES represents a fascinating example of how a small structural modification — the loss of just three amino acids — can dramatically alter a peptide’s functional profile. By evading the binding proteins that normally regulate IGF-1 bioavailability, des(1-3) IGF-1 delivers approximately 10-fold greater potency at the IGF-1 receptor compared to the full-length growth factor.

The preclinical evidence supporting IGF-1 DES benefits in muscle cell proliferation, myogenesis, and wound healing is consistent and mechanistically well-understood. Its role in neuroprotection research, particularly regarding ischemic brain injury, adds an additional dimension to its potential applications.

However, the compound’s very short half-life, absence of clinical trial data, and the inherent mitogenic risks associated with potent IGF-1R activation all limit its current practical significance. Compared to IGF-1 LR3, it offers greater acute potency but far less sustained activity. Compared to indirect GH/IGF-1 axis stimulators like ipamorelin or CJC-1295, it provides a more direct but less physiologically regulated mechanism of action.

For now, IGF-1 DES remains a valuable research tool with moderate evidence confidence — well-characterised at the molecular level but awaiting the clinical investigation needed to understand its full potential and risks in human subjects.

FAQ

What is IGF-1 DES?

IGF-1 DES (des(1-3) IGF-1) is a naturally occurring truncated form of insulin-like growth factor 1 that is missing the first three amino acids (Gly-Pro-Glu) from its N-terminus. This structural modification dramatically reduces its affinity for IGF binding proteins, resulting in approximately 10-fold greater biological potency than full-length IGF-1 in cell-based assays.

How does IGF-1 DES differ from regular IGF-1?

The key difference is IGFBP binding. Full-length IGF-1 is over 95% bound to IGF binding proteins in circulation, which limits its bioavailability. Des(1-3) IGF-1 evades this sequestration, meaning far more of the compound reaches the IGF-1 receptor. Both bind the same receptor with similar affinity, but IGF-1 DES produces stronger net effects because more of it is available in free form.

What is the half-life of IGF-1 DES?

The half-life of IGF-1 DES is approximately 20–30 minutes, making it one of the shortest-acting IGF-1 variants. This is significantly shorter than IGF-1 LR3 (~20–30 hours) and even shorter than native IGF-1 when bound to IGFBPs.

Is IGF-1 DES the same as igf des 1-3?

Yes. IGF-1 DES, igf des 1-3, des(1-3) IGF-1, and des-IGF-I all refer to the same compound — the truncated form of IGF-1 missing its first three N-terminal amino acid residues.

What are the main IGF-1 DES benefits shown in research?

Preclinical research suggests IGF-1 DES benefits include enhanced muscle cell proliferation and differentiation, promotion of wound healing processes, neuroprotective potential, and potent activation of protein synthesis pathways. However, all of this evidence comes from cell culture and animal studies — no human clinical trials have been conducted.

What are the IGF-1 DES side effects?

The primary IGF-1 DES side effects of concern are hypoglycaemia (blood sugar reduction due to IGF-1R activation) and potential mitogenic risk (promotion of cell proliferation, including possible effects on pre-existing tumours). The absence of clinical safety data means the full side effect profile is not yet established.

How does IGF-1 DES compare to IGF-1 LR3?

IGF-1 DES vs IGF-1 LR3 is primarily a question of duration. IGF-1 DES has a ~20–30 minute half-life and produces a brief, intense burst of IGF-1R activation. IGF-1 LR3 has a ~20–30 hour half-life, providing sustained signalling. Both evade IGFBPs, but through different mechanisms — truncation (DES) versus extension and substitution (LR3). IGF-1 DES is naturally occurring; IGF-1 LR3 is entirely synthetic.

Is IGF-1 DES naturally occurring?

Yes. Des(1-3) IGF-1 was originally discovered in bovine colostrum and human brain tissue. It is produced endogenously through proteolytic cleavage of full-length IGF-1, and is thought to play a role in local tissue-specific growth factor signalling, particularly in the central nervous system.

Why is IGF-1 DES used in cell culture?

Des(1-3) IGF-1 is widely used in cell culture because its reduced IGFBP binding means it remains biologically active in media containing serum proteins. Full-length IGF-1 added to cell cultures is largely sequestered by binding proteins present in the media, reducing its effective concentration. IGF-1 DES bypasses this problem, delivering more consistent and potent growth factor stimulation.

Is there any clinical evidence for IGF-1 DES?

No. As of the current evidence base, there are no published human clinical trials investigating des(1-3) IGF-1 for any therapeutic indication. All available data comes from in vitro cell culture studies and animal experiments. This places IGF-1 DES firmly in the preclinical research category.

References

1. Hsieh T et al. “Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF-binding proteins.” J Biol Chem, 2003. PubMed
2. Yang F et al. “Effect of insulin-like growth factor (IGF)-I and Des (1-3) IGF-I on the level of IGF binding protein-3 and IGF binding protein-3 mRNA in cultured porcine embryonic muscle cells.” J Cell Physiol, 1999. PubMed
3. Damon SE et al. “Retrovirally mediated overexpression of insulin-like growth factor binding protein 4: evidence that insulin-like growth factor is required for skeletal muscle differentiation.” J Cell Physiol, 1998. PubMed
4. Galiano RD et al. “Interaction between the insulin-like growth factor family and the integrin receptor family in tissue repair processes. Evidence in a rabbit ear dermal ulcer model.” J Clin Invest, 1996. PubMed
5. Brearley MC et al. “Response of the porcine MYH4-promoter and MYH4-expressing myotubes to known anabolic and catabolic agents in vitro.” Biochem Biophys Rep, 2021. PubMed
6. Guan J. “Insulin-like growth factor-1 and its derivatives: potential pharmaceutical application for ischemic brain injury.” Recent Pat CNS Drug Discov, 2008. PubMed
7. Hadsell DL et al. “Overexpression of des(1-3) insulin-like growth factor 1 in the mammary glands of transgenic mice delays the loss of milk production with prolonged lactation.” Biol Reprod, 2005. PubMed
8. Mongongu C et al. “Detection of LongR(3)-IGF-I, Des(1-3)-IGF-I, and R(3)-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes.” Drug Test Anal, 2021. PubMed

IGF-1 LR3 — sometimes written as IGF 1 LR3, Long R3 IGF-1, or LR3IGF-I — is a synthetic analog of human insulin-like growth factor 1. The name itself describes two specific structural modifications:

• “Long” — a 13-amino-acid N-terminal extension peptide added to the native IGF-1 sequence.
• “R3” — a substitution of glutamic acid (Glu) with arginine (Arg) at position 3 of the mature IGF-1 sequence.

Together, these modifications produce an 83-amino-acid peptide (versus 70 for native IGF-1) with the molecular formula C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉, a molecular weight of approximately 9,111 g/mol, and CAS number 946870-92-4.[2] The critical functional consequence: IGF-1 LR3 binds very poorly to the six known IGFBPs that normally sequester and regulate endogenous IGF-1 in circulation.[1][7][8] This is the single most important distinction between LR3 and the native growth factor.

The original characterisation of these IGF-1 analogs — including the Arg3 substitution — was published by King, Francis, and colleagues in 1992, who demonstrated that reduced IGFBP binding rather than enhanced receptor affinity explained the increased potency of these variants.[2]

Compound Profile

Mechanism of Action

The IGF-1 mechanism centres on activation of the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase structurally related to the insulin receptor. When IGF-1 LR3 binds the IGF-1R, it triggers receptor autophosphorylation and activation of two primary downstream cascades:[4]

• PI3K/Akt/mTOR pathway — drives protein synthesis, cell survival (anti-apoptotic signalling), and glucose uptake. This is the primary anabolic signalling axis relevant to muscle hypertrophy research.
• Ras/MAPK/ERK pathway — promotes cell proliferation and differentiation, with important implications for both tissue growth and proliferative risk.

Laviola et al. (2007) provided a comprehensive review of IGF-I signal transduction, noting that IGF-1R activation leads to tyrosine phosphorylation of multiple substrates including IRS proteins and Shc, ultimately responsible for cell proliferation, tissue differentiation modulation, and protection from apoptosis.[4] These pathways operate identically whether activated by native IGF-1 or the LR3 variant — the difference is duration and magnitude of exposure, not the downstream signalling itself.

Critically, IGF-1 acts through both endocrine (circulating) and autocrine/paracrine (locally produced) mechanisms. Endogenous IGF-1 is primarily produced by the liver in response to growth hormone (GH) stimulation, but skeletal muscle, bone, and other tissues also produce IGF-1 locally.[5][6] The IGF-1 LR3 variant bypasses the normal regulatory checkpoints that limit how long circulating IGF-1 remains bioactive.

Why LR3? The IGFBP Problem

Understanding why LR3 was engineered requires understanding the IGFBP system. In normal physiology, approximately 98% of circulating IGF-1 is bound to one of six IGF binding proteins (IGFBP-1 through IGFBP-6). The majority exists in a 150 kDa ternary complex with IGFBP-3 and the acid-labile subunit (ALS).[6][7][8]

This binding serves several functions:

• Extends half-life — free IGF-1 has a half-life of approximately 10–12 minutes; IGFBP-bound IGF-1 persists for hours.
• Controls bioavailability — only free (unbound) IGF-1 can activate the IGF-1R.
• Provides tissue-specific regulation — different IGFBPs are expressed in different tissues, creating localised control of IGF-1 action.

Bach (2015) and Forbes et al. (2012) reviewed the structural basis of IGFBP function extensively, demonstrating that these binding proteins act as both reservoirs and regulators of IGF bioactivity.[7][8] The system is elegant: it prevents uncontrolled IGF-1R activation while maintaining a large circulating reservoir that can be released locally through IGFBP proteolysis.

The LR3 modification effectively circumvents this entire regulatory system. By dramatically reducing IGFBP affinity, Long R3 IGF-1 remains in its free, bioactive form for far longer — producing the extended ~20–30 hour half-life that distinguishes it from native IGF-1.[1][2] This is simultaneously what makes it a useful research tool and what raises significant safety concerns: the normal braking system for IGF-1 signalling is largely removed.

Muscle & Hypertrophy Research

The anabolic potential of IGF-1 LR3 has been the primary driver of research interest. The foundational study by Tomas et al. (1993) demonstrated that LR3IGF-I was substantially more potent than native IGF-1 in promoting anabolic effects in rats — a daily dose of 44 μg/day of the LR3 variant produced effects comparable to 278 μg/day of native IGF-1 (roughly 6-fold greater potency).[1] Effects included increased body weight gain, improved nitrogen retention, greater food conversion efficiency, and increased muscle protein synthesis.

At the cellular level, IGF-1 signalling through PI3K/Akt/mTOR promotes:

• Satellite cell activation and proliferation — key to muscle fibre repair and hypertrophy.
• Increased protein synthesis — via mTOR-mediated translation initiation.
• Reduced protein degradation — through inhibition of the ubiquitin-proteasome pathway.

Philippou et al. (2007) reviewed the role of IGF-1 isoforms in skeletal muscle physiology, highlighting that locally expressed, mechanically sensitive IGF-1 isoforms regulate the competing processes of cellular proliferation and differentiation required for muscle repair and hypertrophy.[3] Xi et al. (2004) specifically examined Long-R3-IGF-I effects on L6 myogenic cells, demonstrating that IGFBP-3 suppresses both IGF-I and Long-R3-IGF-I-stimulated proliferation — providing important mechanistic data on how the IGFBP bypass operates at the cellular level.[9]

However, a critical caveat: the Tomas et al. study and most subsequent research used animal models. There are no published controlled human trials specifically examining IGF-1 LR3 for muscle hypertrophy outcomes. The translation gap between rat anabolism data and human physiology remains significant.

Metabolic & Body Composition Effects

Beyond direct anabolic effects, IGF-1 signalling influences broader metabolic pathways relevant to body composition. Clemmons (2012) reviewed the metabolic actions of IGF-I, noting that it stimulates protein synthesis in muscle while also promoting free fatty acid utilisation and enhancing insulin sensitivity.[5] These properties suggest a nutrient-partitioning effect — directing calories toward lean tissue rather than fat storage.

Key metabolic actions associated with IGF-1R activation include:

• Glucose uptake — IGF-1 can stimulate glucose transport through a mechanism partially overlapping with insulin signalling.
• Fatty acid oxidation — promotion of fat as a fuel substrate.
• Protein synthesis prioritisation — enhanced nitrogen retention observed in animal models.[1][5]

Conlon et al. (1995) infused Long R3 IGF-I into guinea pigs and observed organ growth effects but no significant changes in body weight, feed intake, or carcass composition — though the study did note that LR3IGF-I reduced endogenous IGF-I, IGF-II, and IGFBP concentrations, suggesting negative feedback effects.[10] This is an important finding: exogenous IGF-1 LR3 may suppress the body’s own IGF system, and the net metabolic impact is not straightforwardly additive.

The metabolic evidence for IGF-1 LR3 specifically remains limited. Most understanding is extrapolated from endogenous IGF-1 physiology and clinical studies using recombinant human IGF-1 (mecasermin) in conditions like severe insulin resistance.[5]

Side Effects & Safety Concerns

The IGF-1 side effects profile — and IGF-1 LR3 side effects specifically — demands honest discussion. Because LR3 removes the normal IGFBP regulatory brake on IGF-1 signalling, several serious concerns emerge:

Hypoglycaemia

IGF-1 has insulin-like metabolic effects, including glucose uptake stimulation. Clemmons (2012) noted that patients receiving IGF-1 are sensitive to hypoglycaemic side effects.[5] The extended bioavailability of LR3 may prolong this risk window.

Organ Growth (Organomegaly)

Both Tomas et al. (1993) and Conlon et al. (1995) observed organ weight changes in animals receiving IGF-1 analogs.[1][10] Sustained IGF-1R activation promotes cell growth across all tissues — not selectively in skeletal muscle. Gut, heart, kidney, and other organs may respond to prolonged IGF-1 signalling.

Proliferative and Cancer Risk

This is the most significant safety concern. The PI3K/Akt/mTOR and Ras/MAPK pathways activated by IGF-1R are the same pathways implicated in tumour cell survival and proliferation.[4][6] Yakar et al. (2002) explicitly noted the role of IGF-I in cancer biology.[6] Epidemiological studies have linked higher circulating IGF-1 levels with increased risk of certain cancers. While correlation does not establish causation, the mechanistic logic is clear: sustained, unregulated IGF-1R activation promotes cell survival and proliferation — precisely the conditions that favour tumour growth. This risk is not theoretical; it is a direct and predictable consequence of the mechanism of action.

WADA Prohibition

IGF-1 LR3 is classified under WADA’s S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It is prohibited at all times, both in-competition and out-of-competition, in all WADA-governed sports.

Suppression of Endogenous IGF System

Conlon et al. (1995) demonstrated that LR3IGF-I infusion reduced plasma concentrations of endogenous IGF-I, IGF-II, and IGF binding proteins.[10] This suggests negative feedback suppression of the body’s own growth factor system — a consideration for any research protocol.

Half-Life & Pharmacokinetics

The pharmacokinetic profile of IGF-1 LR3 is defined almost entirely by its IGFBP bypass mechanism. Native IGF-1 in its free form has a half-life of approximately 10–12 minutes — extremely short. However, when bound in the 150 kDa ternary complex (IGF-1 + IGFBP-3 + ALS), the effective half-life extends to 12–15 hours.[6][7]

IGF-1 LR3 achieves an estimated half-life of ~20–30 hours through the opposite mechanism: rather than being stabilised by binding proteins, it simply avoids being bound in the first place. This means it circulates in its free, bioactive form for extended periods.[1][2] The practical consequence is prolonged, relatively constant IGF-1R activation — in contrast to the pulsatile, IGFBP-regulated pattern of endogenous IGF-1 signalling.

This pharmacokinetic profile explains both the enhanced potency observed in animal studies and the safety concerns: normal IGF-1 signalling is tightly regulated in amplitude and duration; LR3 removes both of those constraints.

FAQ

What is IGF-1 LR3 and how does it differ from regular IGF-1?

IGF-1 LR3 is a modified 83-amino-acid analog of the natural 70-amino-acid insulin-like growth factor 1. The “Long” refers to a 13-amino-acid N-terminal extension, and “R3” refers to an arginine substitution at position 3. These modifications drastically reduce binding to IGF binding proteins (IGFBPs), extending the half-life from minutes (free IGF-1) to approximately 20–30 hours. The IGF-1 LR3 peptide activates the same receptor as native IGF-1 but remains bioactive for much longer.[1][2]

What are the IGF-1 LR3 benefits studied in research?

The primary IGF-1 LR3 benefits investigated in preclinical research include increased protein synthesis, enhanced nitrogen retention, satellite cell activation relevant to muscle hypertrophy, and nutrient-partitioning effects. Tomas et al. (1993) demonstrated approximately 6-fold greater anabolic potency compared to native IGF-1 in rat models.[1] However, these IGF-1 benefits have not been confirmed in controlled human trials for the LR3 variant specifically.

What are the known IGF-1 LR3 side effects?

Documented IGF-1 LR3 side effects in preclinical research include hypoglycaemia, organ growth (organomegaly), suppression of endogenous IGF system components, and theoretical proliferative/cancer risk from sustained IGF-1R activation.[1][5][6][10] The IGF-1 side effects profile for LR3 is potentially more pronounced than for native IGF-1 due to the extended half-life and lack of IGFBP regulation.

Is IGF-1 LR3 approved for human use?

No. IGF-1 LR3 is not FDA-approved and is not approved by any regulatory agency for human therapeutic use. It is classified as a research compound. Recombinant human IGF-1 (mecasermin/Increlex) is FDA-approved for severe primary IGF-1 deficiency, but that is the native 70-amino-acid peptide — not the LR3 variant.

How does IGF-1 LR3 compare to GH secretagogues for muscle growth research?

GH secretagogues (e.g., CJC-1295, ipamorelin) work upstream by stimulating natural GH release, which then increases endogenous IGF-1 through regulated pathways. IGF-1 LR3 works downstream, delivering a modified growth factor that bypasses normal regulation. GH secretagogues preserve physiological feedback loops; IGF-1 LR3 circumvents them. The human safety evidence is substantially stronger for GH secretagogues.

Is IGF-1 LR3 banned in sport?

Yes. IGF-1 LR3 is prohibited at all times by the World Anti-Doping Agency (WADA) under category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. This applies to all WADA-governed sports, both in-competition and out-of-competition.

What is the cancer risk associated with IGF-1 signalling?

Sustained IGF-1R activation promotes cell survival and proliferation through PI3K/Akt/mTOR and Ras/MAPK pathways — the same pathways implicated in tumour biology.[4][6] Epidemiological data associate higher circulating IGF-1 with increased risk of certain cancers. While the LR3 variant has not been studied specifically in this context, its mechanism of extended, unregulated IGF-1R activation is consistent with elevated proliferative risk. This is a genuine concern, not a theoretical one.

How strong is the evidence for IGF-1 LR3 specifically?

Evidence confidence for IGF-1 LR3 is limited. The literature is dominated by in vitro cell culture studies and animal models.[1][9][10] Most human IGF-1 research uses the native peptide (mecasermin) rather than the LR3 variant. Extrapolating from endogenous IGF-1 biology is reasonable but not equivalent to direct evidence. Any interpretation should weight this translation gap appropriately.

References

1. Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993;137(3):413-421. PMID: 8371075. PubMed.
2. King R, Wells JR, Krieg P, Snoswell M, Brazier J, Bagley CJ, Wallace JC, Ballard FJ, Ross M, Francis GL. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3. J Mol Endocrinol. 1992;8(1):29-41. PMID: 1311930. PubMed.
3. Philippou A, Halapas A, Maridaki M, Koutsilieris M. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo. 2007;21(1):45-54. PMID: 17354613. PubMed.
4. Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. Curr Pharm Des. 2007;13(7):663-669. PMID: 17346182. PubMed.
5. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012;41(2):425-443. PMID: 22682639. PubMed.
6. Yakar S, Wu Y, Setser J, Rosen CJ. The role of circulating IGF-I: lessons from human and animal models. Endocrine. 2002;19(3):239-248. PMID: 12624423. PubMed.
7. Bach LA. Insulin-like growth factor binding proteins 4-6. Best Pract Res Clin Endocrinol Metab. 2015;29(5):713-722. PMID: 26522456. PubMed.
8. Forbes BE, McCarthy P, Norton RS. Insulin-like growth factor binding proteins: a structural perspective. Front Endocrinol (Lausanne). 2012;3:38. PMID: 22654863. PubMed.
9. Xi G, Kamanga-Sollo E, Pampusch MS, White ME, Hathaway MR, Dayton WR. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. J Cell Physiol. 2004;200(3):387-394. PMID: 15254966. PubMed.
10. Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):247-253. PMID: 7561636. PubMed.

If your query is what is tesamorelin, the practical answer is: tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that is the only GHRH-pathway peptide with FDA approval (marketed as Egrifta® and Egrifta SV®). It was approved specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.[1][2]

What distinguishes tesamorelin peptide from other GH-axis compounds is the depth of its clinical evidence base. Unlike most research peptides discussed on this site, tesamorelin has been evaluated in multiple randomised, double-blind, placebo-controlled trials — including studies published in JAMA and The Lancet HIV.[3][4] This clinical pedigree makes it the gold-standard reference point for the entire GHRH analog class.

Tesamorelin works by stimulating the anterior pituitary to release growth hormone in a pulsatile pattern, which then drives hepatic IGF-1 production. The downstream effects include visceral fat reduction, improved body composition, favourable metabolic marker changes, and emerging evidence for hepatoprotective and cognitive benefits.[3][4][5]

For context across the GH-axis peptide class, this page pairs naturally with CJC-1295 (a longer-acting GHRH analog without FDA approval), Sermorelin (a shorter-acting GHRH analog), and Ipamorelin (a GH secretagogue that works via the ghrelin receptor rather than GHRH).

Compound Profile

What Does Tesamorelin Actually Do?

Tesamorelin stimulates the anterior pituitary to release growth hormone, which then drives IGF-1 production and downstream metabolic effects. Unlike exogenous GH administration, tesamorelin preserves pulsatile GH secretion patterns and maintains hypothalamic-pituitary feedback regulation.[1][6]

Key findings from clinical trials:

• Visceral fat reduction: the landmark Stanley et al. (2014) JAMA trial demonstrated significant reductions in both visceral adipose tissue and liver fat in HIV-infected patients with abdominal fat accumulation.[3]
• Liver fat reduction (NAFLD): Stanley et al. (2019) in The Lancet HIV showed tesamorelin significantly reduced hepatic fat fraction and prevented NAFLD progression, with improved liver fibrosis markers.[4]
• Body composition improvement: the 2026 Badran et al. meta-analysis pooling multiple RCTs confirmed significant reductions in visceral adipose tissue, trunk fat, and waist circumference, with concurrent improvements in lean body mass.[7]
• Metabolic improvements: improved triglyceride levels, reduced inflammatory markers, and favourable changes in adipose tissue quality documented across multiple trials.[8][9]
• Cognitive function: Baker et al. (2012) demonstrated that GHRH administration (using a tesamorelin analog protocol) improved cognitive function in both healthy older adults and adults with mild cognitive impairment — a finding that broadens the potential application beyond body composition.[5]

How Tesamorelin Works

Tesamorelin is a modified form of human GHRH(1-44)-NH₂ with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This modification enhances stability and receptor binding while maintaining full biological activity at the GHRH receptor.[1][2]

The mechanism operates through a well-characterised pathway:

• GHRH receptor activation: tesamorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering GH synthesis and pulsatile release.[1][6]
• Pulsatile GH secretion: Stanley et al. (2011) specifically demonstrated that tesamorelin augments endogenous GH pulsatility — increasing both pulse amplitude and mean GH levels — while preserving the body’s natural secretory rhythm. This is pharmacologically important because pulsatile GH is more effective than continuous GH exposure for downstream metabolic effects.[6]
• IGF-1 cascade: elevated GH stimulates hepatic IGF-1 production, which mediates effects on body composition, tissue repair, and metabolic regulation.[3][7]
• Visceral adipose targeting: the preferential reduction in visceral (not subcutaneous) fat suggests pathway-specific lipolytic signalling, likely mediated through GH’s known effects on visceral adipocyte lipolysis and lipid oxidation.[3][8]
• Hepatoprotective effects: Fourman et al. (2020) used transcriptomic analysis to show that tesamorelin modulates hepatic gene expression in ways that reduce lipogenesis and inflammation, providing mechanistic insight into the NAFLD benefits.[10]

Fat Loss and Body Recomp Context

Fat loss and body recomposition is tesamorelin’s strongest evidence domain. The clinical trial data is more robust here than for any other peptide on this site.

The evidence hierarchy:

• JAMA RCT (2014): Stanley et al. demonstrated significant reductions in visceral adipose tissue (VAT) and liver fat over 12 months in a double-blind, placebo-controlled trial. The visceral fat reduction was maintained throughout the treatment period.[3]
• 2026 Meta-analysis: Badran et al. pooled data from multiple randomised controlled trials and confirmed consistent reductions in trunk fat, VAT, and waist circumference, with concurrent increases in lean body mass. The effect sizes were statistically and clinically significant.[7]
• Fat quality improvements: Lake et al. (2021) showed tesamorelin improves adipose tissue quality independent of quantity changes — reducing adipose tissue inflammation and improving metabolic function even before visible fat loss occurs.[9]
• Muscle composition: Adrian et al. (2019) demonstrated tesamorelin decreases intermuscular fat and increases muscle area in adults with HIV, suggesting body recomposition effects beyond simple fat reduction.[11]

The key distinction: tesamorelin’s fat loss evidence is strongest for visceral fat specifically. Subcutaneous fat reduction is less pronounced. This makes it particularly relevant for metabolic health contexts where visceral adiposity drives disease risk.

Metabolic Health and Insulin Sensitivity Context

Metabolic health and insulin sensitivity is a critical evaluation axis for tesamorelin, especially given GH’s known insulin-antagonistic effects.

• Insulin sensitivity in healthy men: Stanley et al. (2011) demonstrated that tesamorelin does not worsen insulin sensitivity in healthy subjects during GH pulsatility augmentation, an important safety signal for a GH-axis compound.[6]
• Type 2 diabetes safety: Clemmons et al. (2017) specifically evaluated tesamorelin in patients with type 2 diabetes and found acceptable metabolic safety — HbA1c did not significantly change despite GH-axis stimulation. This directly addresses the concern about GH-mediated glucose dysregulation.[12]
• Metabolic marker improvements: reductions in triglycerides, improved adipokine profiles, and reduced inflammatory markers documented across multiple trials suggest net metabolic benefit despite theoretical GH-insulin interactions.[7][8]
• Visceral fat as metabolic driver: because visceral adipose tissue is a primary driver of insulin resistance and metabolic syndrome, tesamorelin’s preferential VAT reduction may improve metabolic health through adipose reduction independent of direct insulin effects.[3][8]

The practical interpretation: tesamorelin appears to have acceptable metabolic safety even in diabetic populations, and the visceral fat reduction likely produces net metabolic benefit. Glucose monitoring remains appropriate with any GH-axis intervention.[6][12]

NAFLD and Liver Health Context

Non-alcoholic fatty liver disease (NAFLD) reduction is one of tesamorelin’s most compelling emerging applications, with high-quality trial data from The Lancet HIV.

• Lancet HIV RCT (2019): Stanley et al. conducted a randomised, double-blind, multicentre trial showing tesamorelin significantly reduced hepatic fat fraction and prevented NAFLD progression over 12 months. Among participants with NAFLD at baseline, tesamorelin resolved NAFLD in a significant proportion.[4]
• Liver enzyme improvements: Fourman et al. (2017) demonstrated that visceral fat reduction with tesamorelin is associated with improved liver enzymes (ALT, AST), linking the body composition changes to hepatic health markers.[8]
• Hepatic transcriptomic changes: Fourman et al. (2020) used liver biopsy transcriptomics to show tesamorelin downregulates hepatic lipogenesis and inflammatory gene expression, providing mechanistic evidence for liver fat reduction beyond simple GH elevation.[10]

This NAFLD data is particularly significant because no other research peptide on this site has liver-specific clinical trial evidence of this quality. While the trials were conducted in HIV-associated NAFLD, the mechanistic pathways are relevant to general NAFLD, and broader population studies are anticipated.

Cognitive Function Context

Cognitive enhancement is an emerging and genuinely interesting application for GHRH analogs including tesamorelin.

Baker et al. (2012) published in Archives of Neurology a study demonstrating that GHRH administration improved cognitive function in both healthy older adults and adults with mild cognitive impairment (MCI). The improvements were observed across multiple cognitive domains including executive function, verbal memory, and visuospatial processing.[5]

The rationale: GH and IGF-1 are known to have neurotrophic effects, supporting neuronal survival, synaptic plasticity, and cerebral blood flow. Age-related GH decline may contribute to cognitive decline through reduced IGF-1-mediated neuroprotection. GHRH-pathway stimulation via tesamorelin could potentially address this mechanism.[5]

Important caveat: this is a single study using a GHRH protocol, not a dedicated tesamorelin cognitive trial. The finding is promising and mechanistically grounded, but replication in larger populations is needed before cognitive enhancement can be considered a validated tesamorelin application.

Tesamorelin Benefits

Tesamorelin benefits are best understood through the clinical evidence hierarchy — stronger here than for any other GHRH analog:

• Visceral fat reduction: the most robustly demonstrated benefit, confirmed across multiple RCTs and a 2026 meta-analysis. Clinically and statistically significant reductions in VAT, trunk fat, and waist circumference.[3][7]
• NAFLD improvement: significant hepatic fat reduction and NAFLD resolution demonstrated in a Lancet HIV multicentre RCT.[4]
• Body recomposition: concurrent lean mass increases alongside fat reduction, with improved muscle-to-fat ratios documented in multiple studies.[7][11]
• Metabolic marker improvements: reduced triglycerides, improved inflammatory markers, better adipose tissue quality.[8][9]
• Preserved pulsatile GH secretion: augments natural GH pulsatility rather than replacing it, maintaining physiological regulation.[6]
• Cognitive function improvement: early evidence for benefits in executive function and verbal memory in older adults.[5]
• FDA-approved safety profile: tesamorelin is the only GHRH analog with an established regulatory safety and efficacy record.[1][2]

The practical takeaway: tesamorelin has the strongest evidence base of any GHRH analog, with clinical trial quality that far exceeds the typical research peptide. Benefits of tesamorelin are most clearly demonstrated for visceral fat reduction and liver health, with emerging signals for cognition and broader metabolic improvement.[7]

Tesamorelin Side Effects

For tesamorelin side effects intent, the safety profile benefits from extensive clinical trial data and FDA post-marketing surveillance:

• Injection site reactions: the most commonly reported adverse event across all trials — redness, swelling, itching, or pain at the injection site. Generally mild and self-limiting.[1][2]
• Arthralgia (joint pain): reported in clinical trials, likely related to GH/IGF-1 elevation. Usually mild to moderate.[2][7]
• Peripheral oedema: fluid retention effects consistent with GH-axis stimulation. Typically transient and manageable.[2]
• Paraesthesia: tingling or numbness, particularly in extremities. A known GH-related effect.[2]
• Glucose metabolism effects: GH has known insulin-antagonistic properties. However, Clemmons et al. (2017) found tesamorelin did not significantly worsen glycaemic control in type 2 diabetic patients.[12] Glucose monitoring remains appropriate.
• Hypersensitivity reactions: rare but documented in prescribing information. Contraindicated in patients with known hypersensitivity to tesamorelin or mannitol.[2]

The 2026 Badran meta-analysis confirmed that tesamorelin’s overall safety profile across pooled RCTs is acceptable, with adverse events predominantly mild and injection-site-related.[7] The Russo et al. (2024) study in patients on integrase inhibitors further confirmed tolerability in contemporary antiretroviral therapy contexts.[13]

Half-Life

Tesamorelin has a plasma half-life of approximately 26 minutes after subcutaneous injection. Despite this relatively short half-life, the downstream GH and IGF-1 effects persist substantially longer due to the cascade nature of the signalling pathway.[1][2]

For comparison within the GHRH analog class:

• Native GHRH: under 10 minutes (rapidly degraded by DPP-IV)
• Sermorelin: approximately 10-20 minutes
• Tesamorelin: approximately 26 minutes (trans-3-hexenoic acid modification provides moderate stability enhancement)
• CJC-1295 without DAC: approximately 30 minutes
• CJC-1295 with DAC: approximately 5-8 days (albumin binding)

Practical takeaway: tesamorelin’s half-life is short, but the GH/IGF-1 response it triggers extends well beyond the peptide’s own plasma persistence. Clinical dosing is typically once daily, and the cumulative metabolic effects build over weeks to months of consistent use.[1][3]

Is Tesamorelin FDA Approved?

Yes. Tesamorelin (marketed as Egrifta® and Egrifta SV®) received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It remains the only GHRH analog with FDA approval for any indication.[1][2]

This regulatory status is significant because it means tesamorelin has undergone the full FDA review process including Phase III clinical trials, manufacturing quality controls, and post-marketing safety surveillance. This level of regulatory scrutiny exceeds that of any other GHRH analog or GH secretagogue peptide currently available.[2]

Important distinction: FDA approval is specifically for HIV-associated lipodystrophy. Use in other populations (general fat loss, anti-aging, cognitive enhancement, Egrifta bodybuilding contexts) would be off-label. The clinical evidence supports broader applications, but the regulatory indication is specific.[1][2]

Limits of Current Evidence

• Clinical trial evidence is strong but population-specific. Most RCTs were conducted in HIV-associated lipodystrophy populations. Whether effect sizes translate identically to non-HIV populations is plausible but not yet confirmed by large-scale trials.[3][4][7]
• NAFLD evidence is promising but limited to HIV-associated NAFLD. The mechanistic pathways are relevant to general NAFLD, but dedicated trials in non-HIV NAFLD populations are needed.[4][10]
• Cognitive evidence is early-stage. The Baker et al. study is a single trial. Replication in larger populations with tesamorelin specifically is needed.[5]
• Long-term effects beyond 12-18 months are less characterised. Most trials run 6-12 months. Post-marketing surveillance provides safety data but limited long-term efficacy tracking.[7]
• Visceral fat regain after discontinuation. Some evidence suggests fat reaccumulation after stopping tesamorelin, raising questions about duration of benefit.[3]
• Cost and access. As an FDA-approved branded product, tesamorelin (Egrifta) is significantly more expensive than other GHRH analogs, which affects practical accessibility outside clinical settings.

Decision rule: tesamorelin has the highest evidence quality in the GHRH analog class. Confidence is strongest for visceral fat reduction in the studied populations. Confidence decreases for non-HIV populations, cognitive claims, and long-term outcome durability. Even so, the overall evidence base far exceeds that of comparable peptides like CJC-1295 or Sermorelin.

Verdict

Tesamorelin occupies a unique position in the peptide landscape: it is the only GHRH analog with FDA approval, the strongest clinical trial evidence base, and the most robust body composition data. For Fat Loss & Recomp and Metabolic Health goals specifically, tesamorelin is the benchmark against which other GH-axis peptides should be measured.[3][7]

The compound’s profile extends beyond fat loss into NAFLD reduction, metabolic marker improvement, body recomposition, and emerging cognitive benefits. The breadth and quality of evidence is unusual for a peptide compound and provides a higher confidence foundation for interpretation than most alternatives.

For navigation, map this profile to Fat Loss & Recomp, Body Recomp, and Metabolic Health / Insulin Sensitivity. Pressure-test against Tesamorelin vs CJC-1295 and Tesamorelin vs Sermorelin, and cross-reference with CJC-1295, Sermorelin, and Ipamorelin for the full GH-axis class comparison.

FAQ

What is tesamorelin?

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile GH secretion from the anterior pituitary. Marketed as Egrifta®, it was approved in 2010 for reduction of excess abdominal fat in HIV-associated lipodystrophy. It has the strongest clinical evidence base of any GHRH analog.[1][2]

What does tesamorelin peptide do?

Tesamorelin activates the GHRH receptor on pituitary somatotroph cells, stimulating growth hormone release while preserving natural pulsatile secretion patterns. Clinical trials demonstrate visceral fat reduction, liver fat reduction, body recomposition, metabolic marker improvements, and emerging cognitive benefits.[3][4][5]

Is tesamorelin FDA approved?

Yes. Tesamorelin received FDA approval in 2010 for HIV-associated lipodystrophy (excess abdominal fat). It is marketed as Egrifta® and Egrifta SV® and is the only GHRH analog with FDA approval. Use for general fat loss, anti-aging, or cognitive enhancement would be off-label.[1][2]

Is tesamorelin a steroid?

No. Tesamorelin is a peptide hormone analog, not an anabolic steroid. It works by stimulating the body’s own growth hormone release through the GHRH receptor pathway. It does not directly affect testosterone or other steroid hormone pathways.[1]

What are tesamorelin benefits?

The most robustly demonstrated benefits include visceral fat reduction (confirmed by meta-analysis), NAFLD improvement (Lancet HIV RCT), body recomposition (increased lean mass alongside fat reduction), metabolic marker improvements, and cognitive function enhancement in older adults. The evidence quality exceeds that of other GHRH analogs.[3][4][5][7]

What are tesamorelin side effects?

Common side effects include injection site reactions (most frequent), arthralgia, peripheral oedema, and paraesthesia. The safety profile across pooled clinical trials is well-characterised, with adverse events predominantly mild. Glucose monitoring is appropriate with any GH-axis compound, though tesamorelin showed acceptable glycaemic safety even in type 2 diabetic patients.[2][7][12]

Tesamorelin dose and tesamorelin dosage: why not listed here?

This page is informational only and does not provide dosing protocols. The FDA-approved prescribing information for Egrifta provides the clinical dosing framework. This profile focuses on mechanism context, evidence quality, and risk-aware interpretation.

How long does it take for tesamorelin to work?

Clinical trials typically show measurable visceral fat reduction within 12-26 weeks, with effects continuing to build over 12 months of consistent use. GH and IGF-1 elevation occurs within days, but the downstream body composition and metabolic effects are gradual and cumulative.[3][7]

Does tesamorelin work for general fat loss?

Clinical evidence demonstrates tesamorelin preferentially reduces visceral (abdominal) fat rather than subcutaneous fat. This is important: if the goal is visible subcutaneous fat reduction, tesamorelin’s profile may not match expectations. Its strength is metabolically significant visceral fat reduction and associated health improvements.[3][7]

Is tesamorelin safe?

Tesamorelin has undergone full FDA regulatory review including Phase III trials and post-marketing surveillance. The 2026 meta-analysis confirmed acceptable safety across pooled RCTs. Side effects are predominantly mild injection-site reactions. It was well tolerated even in metabolically sensitive populations including type 2 diabetics.[7][12][13]

Tesamorelin for muscle growth: does it work?

Tesamorelin has demonstrated increases in lean body mass alongside fat reduction in clinical trials. Adrian et al. (2019) specifically showed decreased intermuscular fat and increased muscle area. However, it is best framed as a body recomposition and recovery support compound rather than a primary muscle-building agent. Effects are mediated through GH/IGF-1 pathways.[7][11]

Is tesamorelin worth it?

For visceral fat reduction and metabolic health improvement, tesamorelin has the strongest evidence of any GHRH analog — including FDA approval and multiple RCTs. The main practical consideration is cost: as a branded pharmaceutical, Egrifta is significantly more expensive than other peptide options. Whether that premium is “worth it” depends on the specific context, goals, and whether the stronger evidence base justifies the cost differential versus alternatives like CJC-1295 or Sermorelin.

References

1. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. PMID: 21668043.
2. Falutz J. Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue. Drugs Today (Barc). 2011;47(10):751-761. PMID: 21695284.
3. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038357.
4. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID: 31611038.
5. Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420-1429. PMID: 22869065.
6. Stanley TL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. PMID: 20943777.
7. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a systematic review and meta-analysis. Obes Res Clin Pract. 2026;20(1):1-12. PMID: 41545261.
8. Fourman LT, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16):2253-2260. PMID: 28832410.
9. Lake JE, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(6):967-972. PMID: 33756511.
10. Fourman LT, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):e140134. PMID: 32701508.
11. Adrian S, et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. PMID: 31237318.
12. Clemmons DR, et al. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. PMID: 28617838.
13. Russo SC, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(11):1622-1629. PMID: 38905488.

If your query is what is sermorelin, the practical answer is: sermorelin (also known as sermorelin acetate or GRF 1-29) is the first 29 amino acids of human growth hormone-releasing hormone (GHRH). It is a historically significant compound — the first GHRH analog to receive FDA approval (as Geref® for paediatric GH deficiency diagnosis and treatment), giving it the longest clinical track record of any GHRH-pathway peptide.[1][2][3]

Sermorelin peptide stimulates the anterior pituitary to release growth hormone in a pulsatile pattern that preserves the body’s natural GH secretory rhythm. Unlike exogenous GH, sermorelin works through the GHRH receptor rather than bypassing pituitary regulation, which is considered physiologically advantageous for maintaining feedback integrity.[1][4]

Khorram et al. (1997) conducted one of the most important sermorelin aging studies, demonstrating that long-term administration of GRF(1-29)-NH₂ in age-advanced men and women produced sustained increases in IGF-1, improvements in lean body mass, and enhanced immune function markers — without the adverse effects associated with exogenous GH.[1][5]

For context across the GH-axis peptide class, this page pairs naturally with CJC-1295 (a modified, longer-acting GHRH analog), Tesamorelin (an FDA-approved GHRH analog with stronger body composition data), and Ipamorelin (a GH secretagogue that works via the ghrelin receptor rather than GHRH).

Compound Profile

What Does Sermorelin Actually Do?

Sermorelin stimulates the anterior pituitary to release growth hormone in pulses that mirror the body’s natural secretory rhythm. The practical result is elevated GH and IGF-1 levels achieved through physiological pathways rather than pharmacological override.[1][2][4]

Key findings from human studies:

• Long-term GH axis restoration in aging: Khorram et al. (1997) administered GRF(1-29)-NH₂ nightly for 16 weeks to men and women aged 55-71. Results: significant increases in 24-hour GH secretion, elevated IGF-1 levels, increased lean body mass, and reduced body fat — with improvements sustained throughout the treatment period.[1]
• Immune function enhancement: in a companion study, Khorram et al. (1997) demonstrated that the same GRF(1-29) protocol increased natural killer cell number, improved lymphocyte proliferation, and enhanced immune responsiveness in elderly subjects.[5]
• Paediatric growth stimulation: Brain et al. (1990) showed that continuous subcutaneous GHRH(1-29)-NH₂ promoted growth over 12 months in short, slowly growing children — the clinical basis for the original FDA approval.[3]
• Sleep-GH relationship: Jessup et al. (2004) demonstrated that endogenous GHRH receptor activation is specifically linked to nocturnal GH secretion, supporting the mechanistic basis for sermorelin’s reported sleep quality effects.[6]
• Body composition in hypogonadal men: Sinha et al. (2020) reviewed GH secretagogues as body composition management tools, noting GHRH analogs like sermorelin as adjuncts for lean mass maintenance and fat reduction in clinical contexts.[7]

How Sermorelin Works

Sermorelin is the native human GHRH(1-29) sequence — the biologically active fragment of the full 44-amino-acid GHRH molecule. Research established that the first 29 amino acids retain full biological activity at the GHRH receptor, making the remaining 15 residues dispensable.[2][4]

The mechanism operates through a well-characterised pathway:

• GHRH receptor binding: sermorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering intracellular cAMP signalling that stimulates both GH synthesis and release.[2][4]
• Pulsatile secretion preservation: unlike exogenous GH, sermorelin works through the hypothalamic-pituitary axis, meaning somatostatin-mediated feedback remains intact. GH is released in natural pulses rather than continuous elevation.[1][4]
• IGF-1 cascade: elevated GH drives hepatic IGF-1 production, which mediates downstream effects on body composition, tissue repair, immune function, and metabolic regulation.[1][5]
• Nocturnal GH amplification: sermorelin administration (typically evening/bedtime) amplifies the largest natural GH pulse, which occurs during slow-wave sleep. Jessup et al. (2004) confirmed the specific link between GHRH receptor activity and nocturnal GH secretion.[6]

The key pharmacological limitation: sermorelin uses the unmodified native GHRH(1-29) sequence, which is rapidly degraded by DPP-IV enzymes. This gives it a very short half-life (~10-20 minutes), requiring precise timing and more frequent administration compared to modified GHRH analogs like CJC-1295 or Tesamorelin.[2][8]

Recovery and Sleep Context

Recovery and sleep is one of sermorelin’s most practically relevant domains. The relationship between GHRH, nocturnal GH secretion, and sleep quality is well-established in the neuroendocrine literature.[6]

The mechanistic basis:

• Sleep-GH coupling: the majority of daily GH secretion occurs during slow-wave (deep) sleep. GHRH receptor activation specifically amplifies this nocturnal pulse. Jessup et al. (2004) demonstrated that blocking endogenous GHRH receptors reduced nocturnal GH secretion without altering sleep architecture — confirming that GHRH drives the GH pulse rather than sleep itself driving GH release.[6]
• Recovery quality: elevated nocturnal GH supports tissue repair, protein synthesis, and glycogen replenishment during sleep. In practical contexts, sermorelin users most commonly report improved recovery feel upon waking and better training readiness.
• Evening dosing rationale: sermorelin’s short half-life and the nocturnal GH pulse timing create a natural dosing window — evening administration amplifies the existing sleep-linked GH surge rather than creating an artificial pattern.

Important caveat: sermorelin may improve the recovery value of sleep (via GH amplification) without necessarily changing sleep duration or architecture. The benefit is more accurately framed as enhanced physiological recovery during sleep rather than a sleep aid.

Muscle Growth and Performance Context

Muscle growth and performance support relevance for sermorelin operates through the GH/IGF-1 axis. Elevated IGF-1 supports protein synthesis, nitrogen retention, and recovery from training-induced tissue damage — but these effects are indirect and baseline-dependent.[1][7]

• Lean body mass increases: Khorram et al. (1997) documented significant lean body mass increases in elderly subjects over 16 weeks of GRF(1-29) administration, alongside reductions in body fat percentage.[1]
• Body composition management: Sinha et al. (2020) positioned GH secretagogues including GHRH analogs as tools for lean mass maintenance and fat reduction, particularly in hypogonadal or aging contexts where GH decline compounds muscle loss.[7]
• Recovery-driven performance: the primary performance mechanism is through improved recovery quality rather than direct anabolic effects. Better recovery between training sessions enables higher training consistency and volume tolerance over time.

Practical interpretation: sermorelin is a recovery and body-composition support compound rather than a direct muscle-building agent. Value is typically most visible in contexts where training fundamentals are stable and outcomes are tracked across multi-week blocks. For dedicated muscle growth goals, sermorelin’s contribution is primarily through recovery optimisation and hormonal environment support.

Longevity and Healthy Aging Context

Longevity and healthy aging is arguably sermorelin’s strongest theoretical domain. The age-related decline in GH secretion (somatopause) is one of the most well-documented endocrine changes of aging, and GHRH analogs represent a more physiological intervention approach than exogenous GH.[1][4][9]

• Somatopause intervention: GH secretion declines approximately 14% per decade after age 30, with corresponding IGF-1 reductions. Merriam et al. (2003) argued that GHRH analogs and GH secretagogues offer a safer, more physiological approach to somatopause than exogenous GH because they preserve pulsatile secretion and hypothalamic-pituitary feedback.[4]
• Multi-system aging benefits: the Khorram studies documented improvements across multiple aging-relevant domains — lean mass, body fat, immune function, and IGF-1 levels — in elderly subjects treated with GRF(1-29).[1][5]
• Immune senescence: Khorram et al. (1997) specifically showed enhanced NK cell activity and lymphocyte function in elderly subjects — addressing immune decline as a component of the aging process.[5]
• Safety advantage: Sattler (2013) noted that GHRH analogs maintain the body’s regulatory feedback mechanisms, reducing the risks associated with supraphysiological GH levels (fluid retention, insulin resistance, joint pain) that can occur with exogenous GH.[9]

The practical positioning for longevity: sermorelin’s pulsatility preservation and physiological approach make it conceptually well-suited for long-term GH-axis support. The trade-off is its short half-life requiring daily dosing, versus newer analogs like CJC-1295 that provide more sustained elevation. Whether sharp, natural-pattern GH pulses (sermorelin) or sustained elevation (CJC-1295) is preferable for longevity remains an open question.[4][8]

Hormonal Support Context

Testosterone and hormonal support relevance for sermorelin is indirect. Sermorelin acts on the GH axis specifically, not the hypothalamic-pituitary-gonadal (HPG) axis that governs testosterone production.[1][4]

However, GH and testosterone systems interact bidirectionally. Sinha et al. (2020) specifically positioned GH secretagogues as adjuncts in hypogonadal management, noting that adequate GH signalling supports the broader endocrine environment. The recovery, sleep, and body composition improvements mediated by GH-axis optimisation may indirectly support hormonal balance.[7][9]

The honest framing: sermorelin is a GH-axis compound with possible indirect hormonal environment benefits. It is not a testosterone replacement or direct androgenic agent. For dedicated hormonal support, evaluate it as part of a broader strategy rather than a standalone intervention.

Sermorelin Benefits

Sermorelin benefits are best understood through the evidence hierarchy:

• Physiological GH axis restoration: stimulates natural pulsatile GH secretion via the GHRH receptor, maintaining hypothalamic-pituitary feedback — the most natural approach to GH-axis support available.[1][2][4]
• Lean body mass improvement: significant increases documented in elderly subjects over 16 weeks, alongside body fat reductions.[1]
• Immune function enhancement: improved NK cell activity and lymphocyte function in aging populations, addressing immune senescence.[5]
• Recovery and sleep support: amplification of nocturnal GH pulses supports tissue repair and recovery quality during sleep.[6]
• Longest clinical safety history: as the first FDA-approved GHRH analog (Geref®, 1997), sermorelin has the longest clinical track record of any compound in its class.[2][3]
• Well-tolerated safety profile: Sigalos & Pastuszak (2018) reviewed GH secretagogues as a class and concluded they have acceptable safety profiles, with sermorelin’s established history providing additional confidence.[8]
• Somatopause mitigation: addresses age-related GH decline through physiological mechanisms rather than pharmacological replacement.[1][4][9]

Evidence-weighted read: multi-system aging benefits (lean mass, immune function, IGF-1) are supported by controlled human studies. Sleep and recovery benefits are mechanistically grounded and practically reported but less formally studied. Benefits of sermorelin are strongest when fundamentals are stable and outcomes are tracked across weeks.[1][5]

Sermorelin Side Effects

For sermorelin side effects intent, the safety profile benefits from sermorelin’s extensive clinical history:

• Injection site reactions: redness, swelling, or discomfort at injection sites. The most commonly reported adverse effect across clinical use.[2][8]
• Flushing: transient warmth or facial flushing after injection, typically resolving within minutes.[2]
• Headache: reported in some subjects, usually mild and transient.[2]
• Dizziness: occasionally reported, generally mild.[2]
• Difficulty swallowing or taste changes: uncommon but documented in prescribing information.[2]
• Antibody formation: long-term use can trigger anti-GHRH antibodies that may reduce efficacy over time. This is a known consideration with peptide therapies and may require periodic evaluation.[2][3]

The Khorram aging studies reported the GRF(1-29) protocol was well tolerated over 16 weeks in elderly subjects, with no serious adverse events.[1][5] Sigalos & Pastuszak’s 2018 safety review confirmed that GH secretagogues as a class have acceptable safety profiles, while noting the need for longer-term surveillance in general use.[8]

Compared to exogenous GH, sermorelin’s side effect profile is generally milder because it works through physiological pathways: fluid retention, joint pain, and insulin resistance — common with exogenous GH — are less frequent with GHRH-pathway stimulation that preserves feedback regulation.[4][8][9]

Half-Life

Sermorelin has a plasma half-life of approximately 10-20 minutes after subcutaneous injection. This is the shortest half-life of any commonly discussed GHRH analog, and it is sermorelin’s primary pharmacological limitation.[2][8]

For comparison within the GHRH analog class:

• Native GHRH (1-44): under 10 minutes (rapidly degraded by DPP-IV)
• Sermorelin (GRF 1-29): approximately 10-20 minutes (slightly more stable than full-length GHRH)
• Tesamorelin: approximately 26 minutes (trans-3-hexenoic acid modification)
• CJC-1295 without DAC: approximately 30 minutes (DPP-IV-resistant modifications)
• CJC-1295 with DAC: approximately 5-8 days (albumin binding)

Practical implications: sermorelin’s short half-life means timing is critical. Evening administration aligns with the natural nocturnal GH surge. The rapid clearance produces a sharp, defined GH pulse followed by return to baseline — which some view as more physiologically natural than sustained elevation, though it requires more precise dosing discipline.[2][6]

Sermorelin for Weight Loss and Fat Loss Context

For sermorelin for weight loss and sermorelin for fat loss intent: body composition improvement through GH-axis stimulation is a frequently discussed application, with supporting evidence from the Khorram aging studies.

• Fat reduction documented: Khorram et al. (1997) showed significant reductions in body fat percentage in elderly subjects over 16 weeks of GRF(1-29) administration.[1]
• Mechanism: GH promotes lipolysis (fat breakdown) primarily through mobilisation of fatty acids from adipose tissue. Elevated GH/IGF-1 from sermorelin stimulation can shift substrate utilisation toward fat oxidation.[1][7]
• Realistic expectations: sermorelin’s fat loss effect is modest compared to dedicated weight loss compounds like semaglutide or tirzepatide. The primary mechanism is gradual body composition improvement (more lean mass, less fat) rather than rapid weight reduction.

The honest assessment: sermorelin can contribute to fat loss as part of a comprehensive approach including training and nutrition, but it is not a standalone weight loss solution. Its strength is body recomposition (improving the ratio) rather than dramatic scale weight reduction. For dedicated fat loss goals, compare against compounds with stronger weight loss evidence.

Limits of Current Evidence

• Key human studies are from the 1990s. The Khorram aging studies remain the most relevant sermorelin-specific human data. Newer research has largely focused on modified analogs (CJC-1295, tesamorelin) rather than native GRF(1-29).[1][5]
• Small sample sizes in aging studies. The Khorram studies used relatively small cohorts. While results are consistent and biologically plausible, larger confirmatory trials would strengthen confidence.[1][5]
• Short half-life is a practical limitation. The 10-20 minute half-life makes sermorelin the least pharmacokinetically convenient option in its class. Modern alternatives offer longer duration of action with comparable or superior efficacy.[2][8]
• FDA approval withdrawn. Geref® was withdrawn from the US market in 2008 for commercial (not safety) reasons, which means sermorelin currently lacks active FDA marketing authorisation.[2]
• Antibody formation. Long-term use may trigger anti-GHRH antibodies that reduce efficacy, a consideration for sustained use.[2][3]
• Limited head-to-head comparisons. No direct clinical trials compare sermorelin to CJC-1295 or tesamorelin in matched populations. Relative positioning is inferred from independent study results and mechanistic reasoning.

Decision rule: sermorelin has solid human evidence for GH-axis stimulation and multi-system aging benefits, but the evidence base is older and smaller than for newer GHRH analogs. Its primary advantage is the longest clinical safety history and the most physiological approach to GH-axis support. Its primary limitation is pharmacokinetic convenience.

Verdict

Sermorelin is the original GHRH analog — the compound that established the proof of concept for GH-axis stimulation through the pituitary pathway. Its native GRF(1-29) sequence represents the most physiological approach to GH augmentation: preserving pulsatility, maintaining feedback regulation, and amplifying the body’s own GH secretory capacity.[1][2][4]

Where it fits today: sermorelin remains relevant for contexts that prioritise physiological naturalness and safety track record over pharmacokinetic convenience. The Khorram aging studies documented meaningful improvements in lean mass, body fat, IGF-1 levels, and immune function in elderly subjects — a multi-system benefit profile that aligns well with longevity and healthy aging goals.[1][5]

The practical trade-off: newer GHRH analogs like CJC-1295 and Tesamorelin offer longer half-lives, more robust clinical data (tesamorelin especially), and greater dosing convenience. Sermorelin’s value proposition is its native sequence, established safety history, and sharp physiological GH pulsatility — for those who prioritise these characteristics over convenience.

For navigation, map this profile to Longevity / Healthy Aging, Recovery & Sleep, Muscle Growth, and Hormonal Support. Pressure-test with Ipamorelin vs Sermorelin, CJC-1295 vs Sermorelin, and Tesamorelin vs Sermorelin, and cross-reference with GHRP-2 for an alternative secretagogue pathway.

FAQ

What is sermorelin?

Sermorelin (sermorelin acetate, GRF 1-29) is the first 29 amino acids of human growth hormone-releasing hormone. It was the first GHRH analog to receive FDA approval (as Geref® in 1997) and has the longest clinical track record of any GH-axis peptide. It stimulates natural, pulsatile GH secretion through the GHRH receptor.[1][2][3]

What does sermorelin peptide do?

Sermorelin activates the GHRH receptor on pituitary somatotroph cells, stimulating growth hormone synthesis and pulsatile release while preserving natural feedback regulation. Human studies demonstrate increased GH and IGF-1 levels, lean body mass improvements, fat reduction, and enhanced immune function in elderly subjects.[1][5]

What are sermorelin benefits?

Key benefits include physiological GH axis restoration, lean body mass improvement, body fat reduction, immune function enhancement, recovery and sleep support, and somatopause mitigation. Sermorelin has the longest safety history of any GHRH analog. Benefits are most visible when fundamentals (training, nutrition, sleep) are stable and tracked across weeks.[1][5][6]

What are sermorelin side effects?

Common side effects include injection site reactions, transient flushing, headache, and dizziness. The safety profile is generally milder than exogenous GH because sermorelin works through physiological pathways. Long-term use may trigger anti-GHRH antibodies. The Khorram studies reported the compound was well tolerated in elderly subjects.[1][2][8]

Sermorelin dose and sermorelin dosage: why not listed here?

This page is informational only and does not provide dosing protocols. This profile focuses on mechanism context, evidence quality, and risk-aware interpretation. Refer to primary research literature for protocol parameters.

Ipamorelin vs Sermorelin: which pathway and why compare them?

They stimulate GH through completely different receptors. Sermorelin works via the GHRH receptor; Ipamorelin works via the ghrelin receptor (GHS-R). This makes them complementary rather than competitive — they can theoretically be combined for dual-pathway stimulation. See Ipamorelin vs Sermorelin for the full comparison.[4][8]

CJC-1295 vs Sermorelin: what is the useful distinction?

Both are GHRH analogs targeting the same receptor, but CJC-1295 has modified amino acids that resist enzymatic degradation, extending its half-life from sermorelin’s ~10-20 minutes to ~30 minutes (no-DAC) or 5-8 days (with DAC). CJC-1295 offers convenience; sermorelin offers the most natural GH pulse pattern and longest safety history. See CJC-1295 vs Sermorelin.[2][8]

Does sermorelin work for weight loss?

Sermorelin can contribute to body composition improvement (reduced fat, increased lean mass) through GH-axis stimulation. Khorram et al. documented significant fat reduction in elderly subjects. However, it is not a dedicated weight loss compound — for substantial weight reduction, GLP-1 receptor agonists like semaglutide have far stronger evidence.[1]

Is sermorelin FDA approved?

Sermorelin was FDA-approved as Geref® in 1997 for paediatric GH deficiency diagnosis and treatment. The approval was withdrawn from the US market in 2008 for commercial (not safety) reasons. It currently lacks active FDA marketing authorisation but retains its historical regulatory safety record.[2][3]

How long does sermorelin take to work?

GH and IGF-1 elevation occurs within days of starting sermorelin. Body composition and recovery improvements typically become measurable over 4-8 weeks. The Khorram aging studies assessed outcomes at 16 weeks. Judge results by multi-week trends rather than day-to-day impressions.[1]

Is sermorelin safe?

Sermorelin has the longest clinical safety history of any GHRH analog, spanning decades of use. The Khorram studies reported no serious adverse events in elderly subjects over 16 weeks. Sigalos & Pastuszak’s 2018 review confirmed acceptable safety for GH secretagogues as a class. Side effects are generally milder than exogenous GH due to physiological feedback preservation.[1][5][8]

What should be tracked when evaluating sermorelin?

Recovery quality upon waking, training readiness consistency, body composition trends (ideally via DEXA or calibrated measurements), sleep quality impressions, and overall energy levels. Track across 4+ week blocks with controlled fundamentals. Single-day assessments are unreliable due to the many confounding variables that affect these outcomes independently.

References

1. Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH₂ in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PMID: 9141536.
2. Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;14(1):76-86. PMID: 34665524.
3. Brain CE, et al. Continuous subcutaneous GHRH(1-29)-NH₂ promotes growth over 1 year in short, slowly growing children. Clin Endocrinol (Oxf). 1990;32(3):375-386. PMID: 2140733.
4. Merriam GR, et al. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14610297.
5. Khorram O, et al. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH₂ administration on the immune system of aging men and women. J Clin Endocrinol Metab. 1997;82(11):3590-3596. PMID: 9360512.
6. Jessup SK, et al. Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. Eur J Endocrinol. 2004;151(5):561-566. PMID: 15538933.
7. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID: 32257855.
8. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.
9. Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27(4):541-555. PMID: 24054930.
10. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. PMID: 41476424.
11. Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420-1429. PMID: 22869065.

If your query is what is CJC-1295, the practical answer is: CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile growth hormone (GH) secretion from the anterior pituitary. It is one of the most widely discussed CJC-1295 peptide compounds in GH-axis research contexts.[1][2]

In the landmark human study, Teichman et al. (2006) demonstrated that a single dose of CJC-1295 produced sustained 2- to 10-fold increases in GH concentration and 1.5- to 3-fold increases in IGF-1 levels, with effects persisting for up to 6 days after injection. After multiple doses, mean IGF-1 levels increased by 1.5- to 3-fold for 9 to 11 days.[1] This prolonged duration distinguishes CJC-1295 from shorter-acting GHRH analogs like Sermorelin.

Importantly, Ionescu & Bhatt (2006) confirmed that pulsatile GH secretion is preserved during continuous CJC-1295 stimulation, meaning the compound works within the body’s natural secretory rhythm rather than overriding it.[2] This pulsatility preservation is a key pharmacological advantage over exogenous GH administration.

For context across the GH-axis peptide class, this page pairs naturally with Ipamorelin (a GH secretagogue that works via the ghrelin receptor rather than GHRH), Sermorelin (a shorter-acting GHRH analog), and Tesamorelin (a GHRH analog with FDA approval for HIV-associated lipodystrophy).

Compound Profile

What Does CJC-1295 Actually Do?

CJC-1295 peptide stimulates the anterior pituitary to release growth hormone in a pulsatile pattern that mirrors natural GH secretion. The practical effect is an elevated GH/IGF-1 baseline over days rather than hours, which is why CJC-1295 is typically evaluated by multi-week trend quality rather than acute single-dose response.[1][2]

Key findings from human and preclinical data:

• Sustained GH elevation: 2- to 10-fold increases in GH concentration persisting for up to 6 days after a single injection in healthy adults.[1]
• IGF-1 amplification: 1.5- to 3-fold increases in IGF-1 levels sustained for 9 to 11 days after multiple doses, indicating cumulative signalling.[1]
• Pulsatility preservation: unlike exogenous GH, CJC-1295 maintains the body’s natural pulsatile GH secretion pattern, which is considered physiologically important for downstream signalling quality.[2]
• Serum protein profile changes: Sackmann-Sala et al. (2009) documented measurable changes in serum protein profiles in healthy subjects following CJC-1295 administration, suggesting broader systemic effects beyond isolated GH elevation.[3]
• GRF receptor activation: the parent sequence GRF(1-29) activates the GHRH receptor on the anterior pituitary with high specificity, and CJC-1295’s modifications extend this activation window.[4]

The practical interpretation framework: CJC-1295 creates a more favourable GH signalling environment over time. Whether that translates into measurable recovery, body composition, or sleep benefits depends on baseline conditions, training structure, and how consistently fundamentals are controlled.

How CJC-1295 Works

CJC-1295 is a modified version of the first 29 amino acids of growth hormone-releasing hormone (GHRH, also called GRF 1-29). The modifications serve two purposes: protecting the peptide from enzymatic degradation (DPP-IV cleavage) and, in the DAC version, enabling covalent binding to serum albumin for extended half-life.[1][4]

The mechanism operates through a well-characterised pathway:

• GHRH receptor binding: CJC-1295 binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering intracellular cAMP signalling that stimulates GH synthesis and release.[4][5]
• Pulsatile release preservation: the hypothalamic-pituitary feedback loop remains intact during CJC-1295 stimulation, meaning GH is released in pulses rather than continuous elevation. This is pharmacologically significant because pulsatile GH is more effective at driving IGF-1 production and downstream tissue effects than continuous GH exposure.[2]
• IGF-1 cascade: elevated GH stimulates hepatic IGF-1 production, which mediates many of the anabolic, recovery, and body composition effects attributed to the GH axis.[1][3]
• Somatostatin sensitivity retained: CJC-1295 does not override somatostatin (the GH-inhibiting hormone), meaning the body’s natural braking system remains functional. This contrasts with approaches that bypass pituitary regulation entirely.[2][5]

The engineering distinction matters: CJC-1295’s longevity comes from modified amino acids (to resist DPP-IV degradation) and, in the DAC formulation, a Drug Affinity Complex that binds albumin. This extends the effective half-life from minutes (native GHRH) to days.[1][4]

Muscle Growth and Body Recomp Context

Muscle growth and body recomposition relevance for CJC-1295 operates through the GH/IGF-1 axis. Elevated IGF-1 supports protein synthesis, nitrogen retention, and recovery from training-induced muscle damage — but these effects are indirect and baseline-dependent.[1][3]

The evidence context for GH-axis stimulation and body composition:

• IGF-1 and muscle protein synthesis: the 1.5- to 3-fold IGF-1 increases documented with CJC-1295 are within the range associated with improved recovery and anabolic signalling in GH-axis research.[1]
• Tesamorelin precedent: the closely related GHRH analog tesamorelin has demonstrated measurable body composition changes (reduced visceral fat) in clinical trials, providing directional evidence that GHRH-pathway stimulation can influence body composition.[8]
• Age-related GH decline: GH secretion decreases approximately 14% per decade after age 30. GHRH analogs like CJC-1295 are studied as potential interventions for this somatopause decline, particularly for body composition maintenance in aging populations.[6][7]

Practical interpretation: CJC-1295 is more accurately framed as a recovery and body-composition support compound than a direct muscle-building agent. Outcomes are typically most visible when training, nutrition, and sleep fundamentals are stable and tracked across multi-week blocks. For the Fat Loss & Recomp goal specifically, the GH-axis contribution is primarily through improved recovery quality and metabolic support rather than direct lipolysis.

Hormonal Support Context

Testosterone and hormonal support relevance for CJC-1295 is indirect. CJC-1295 acts on the GH axis specifically, not the hypothalamic-pituitary-gonadal (HPG) axis that governs testosterone production.[1][5]

However, GH and testosterone systems interact: adequate GH signalling supports overall endocrine environment quality, and the recovery and sleep improvements associated with GH-axis optimisation can indirectly support hormonal balance. Sattler (2013) reviewed the interplay between GH decline and broader hormonal changes in aging males, noting that GH-axis intervention may support overall endocrine resilience even when testosterone-specific effects are not the primary mechanism.[6]

The honest framing: CJC-1295 is a GH-axis compound with possible indirect hormonal environment benefits. It is not a testosterone replacement or direct androgenic agent.

Longevity and Healthy Aging Context

Longevity and healthy aging is where CJC-1295 intersects with the broader somatopause literature. The age-related decline in GH secretion is well-documented and associated with increased body fat, decreased lean mass, reduced bone density, and impaired recovery capacity.[6][7][9]

Key context from the aging literature:

• Somatopause: GH secretion declines approximately 14% per decade from age 30, with corresponding reductions in IGF-1. This decline is associated with sarcopenia, increased adiposity, and reduced functional capacity.[6][7]
• GHRH analog rationale: Merriam et al. (1997, 2003) argued that GHRH analogs and GH secretagogues represent a more physiological approach to addressing somatopause than exogenous GH, because they preserve pulsatile secretion patterns and hypothalamic-pituitary feedback.[7][9]
• Safety review: Sigalos & Pastuszak (2018) reviewed the safety and efficacy of GH secretagogues as a class, concluding that they offer a potentially safer alternative to exogenous GH for age-related GH decline, though noting that long-term human safety data remains limited.[5]

Interpretation for CJC-1295 specifically: the compound’s pulsatility preservation and sustained IGF-1 elevation make it one of the more pharmacologically interesting GHRH analogs for longevity-oriented research. But “anti-aging” claims should stay evidence-weighted: the rationale is strong, the mechanism is sound, but large-scale long-term human outcome data is not yet available.

Recovery and Sleep Context

Recovery and sleep relevance for CJC-1295 is biologically grounded: the majority of natural GH secretion occurs during slow-wave sleep. By amplifying GH pulsatility, CJC-1295 may enhance the recovery value of sleep without necessarily changing sleep architecture itself.[2][5]

The practical signal is usually reported as improved recovery feel upon waking, better training readiness, and fewer disrupted training blocks. These are indirect outcomes mediated through GH/IGF-1 elevation rather than direct sedative or sleep-promoting effects.

When evaluating recovery claims, the most reliable approach is tracking recovery quality across consistent sleep schedules over multiple weeks. Single-night impressions are unreliable due to the many confounding variables that affect sleep quality independently of GH axis status.

CJC-1295 Benefits

CJC-1295 benefits are best understood through the evidence hierarchy:

• Sustained GH/IGF-1 elevation: the most directly demonstrated benefit, with 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 increases documented in human subjects.[1]
• Preserved pulsatile secretion: unlike exogenous GH, CJC-1295 maintains natural GH pulse patterns, which is pharmacologically significant for downstream signalling quality.[2]
• Extended duration of action: the DAC version provides days of sustained activity from a single injection, reducing administration frequency compared to shorter-acting GHRH analogs.[1][4]
• Recovery support: improved recovery quality and training continuity reported in practical contexts, mediated through GH/IGF-1-dependent tissue repair pathways.[5][10]
• Body composition support: indirect support for lean mass maintenance and fat reduction through improved GH axis signalling, with GHRH-analog class evidence from tesamorelin trials providing directional support.[8]
• Aging-related GH decline mitigation: the somatopause literature supports GHRH analog use as a more physiological approach to age-related GH decline than exogenous GH.[6][7][9]

Evidence-weighted read: GH/IGF-1 elevation is well-documented in humans. Downstream clinical outcomes (body composition, recovery, aging) are supported by mechanism and class-level evidence but lack large-scale CJC-1295-specific outcome trials. Benefits of CJC-1295 are strongest when fundamentals are stable and outcomes are judged by trend quality over weeks.[1][5]

CJC-1295 Side Effects

For CJC-1295 side effects intent, the safety profile draws from the Teichman human study and broader GH secretagogue class data:

• Injection site reactions: redness, swelling, or irritation at injection sites. The most commonly reported adverse effect in the Teichman study.[1]
• Water retention: transient fluid retention and puffiness, consistent with elevated GH/IGF-1 activity. Usually resolves with hydration management.
• Headache: reported in some subjects during clinical evaluation.[1]
• Flushing or warmth: transient post-injection flushing reported in some users.
• Appetite changes: GH axis stimulation can influence appetite patterns, though direction and magnitude vary considerably between individuals.
• Glucose handling concerns: GH has known insulin-antagonistic effects. Sigalos & Pastuszak (2018) noted that glucose metabolism monitoring is appropriate with GH secretagogue use, particularly in metabolically sensitive populations.[5]
• Person-to-person variability: individual responses vary substantially. Attribution is difficult when multiple variables (training, nutrition, sleep) change simultaneously.

The Teichman study reported CJC-1295 was generally well tolerated, with adverse events mostly mild and injection-site-related.[1] Sigalos & Pastuszak’s 2018 review concluded that GH secretagogues as a class have acceptable safety profiles, while noting the need for longer-term surveillance.[5] Weekly trend logging is more reliable than single-day reactions when assessing side effect significance.

Half-Life

For CJC-1295 half-life queries: the half-life varies significantly depending on DAC status.

• CJC-1295 with DAC: approximately 5 to 8 days, owing to covalent albumin binding via the Drug Affinity Complex. This is the version used in the Teichman et al. study, which showed GH effects persisting for up to 6 days after a single dose.[1][4]
• CJC-1295 without DAC (Mod GRF 1-29): approximately 30 minutes. The DPP-IV-resistant amino acid modifications extend the half-life beyond native GHRH (which degrades in under 10 minutes) but without albumin binding, clearance remains relatively rapid.

For comparison: native GHRH has a half-life under 10 minutes. Sermorelin (GRF 1-29 without modifications) has a similarly short half-life. CJC-1295 with DAC represents a roughly 500-fold increase in persistence over native GHRH.[1][4]

Practical takeaway: use half-life as orientation for administration frequency planning, but judge outcomes by weekly recovery and output trends rather than strict pharmacokinetic clock assumptions.

CJC-1295 and Ipamorelin Combination Context

CJC-1295 and Ipamorelin (also searched as CJC-1295 Ipamorelin and CJC 1295 ipamorelin) is one of the most discussed peptide combinations in the GH-axis space. The rationale is pharmacologically sound: the two compounds stimulate GH release through distinct receptor pathways.

• CJC-1295: activates the GHRH receptor on pituitary somatotrophs → signals GH synthesis and release.[1][4]
• Ipamorelin: activates the ghrelin receptor (GHS-R) on somatotrophs → amplifies GH pulse amplitude without affecting other hormone axes (unlike older GH secretagogues like GHRP-6 that also influence cortisol and prolactin).[5][10]

The combination is discussed as potentially synergistic because GHRH-pathway and ghrelin-pathway stimulation are known to produce greater GH release together than either pathway alone.[5] In practical contexts, CJC-1295 ipamorelin benefits discussions typically centre on enhanced recovery quality, improved sleep-linked GH pulsatility, and more consistent training readiness.

Important caveats: no published clinical trial has specifically studied CJC-1295 + Ipamorelin in combination. The synergy rationale is extrapolated from pathway-level pharmacology and class-level GH secretagogue data. See CJC-1295 vs Ipamorelin for the full comparison breakdown.

Limits of Current Evidence

• Human pharmacokinetic and pharmacodynamic data is solid for CJC-1295 with DAC, thanks to the Teichman (2006) and Ionescu (2006) studies. GH/IGF-1 elevation in humans is well-documented.[1][2]
• Clinical outcome data is limited. No large-scale trials have evaluated CJC-1295 for specific clinical endpoints (body composition, recovery, aging). Most outcome evidence comes from class-level GHRH analog data and the tesamorelin precedent.[8]
• CJC-1295 without DAC (Mod GRF 1-29) has minimal published clinical data. Most formal research uses the DAC version. No-DAC pharmacology is largely extrapolated from the parent GRF 1-29 sequence.
• Combination protocols (CJC-1295 + Ipamorelin) lack dedicated clinical trials. Synergy claims are mechanistically reasonable but clinically unconfirmed.
• Long-term safety surveillance is absent. The Teichman study was short-duration. Sigalos & Pastuszak’s safety review is encouraging but acknowledges the need for longer follow-up.[1][5]
• DAC vs no-DAC discussions are often over-simplified. The choice involves pharmacokinetic trade-offs, not categorical superiority.[1]

Decision rule: confidence is highest for GH/IGF-1 elevation in humans. Confidence decreases progressively for specific clinical outcomes, long-term safety, and combination protocol effects.

Verdict

CJC-1295 is one of the best-characterised GHRH analogs in the peptide research space, with human pharmacokinetic data demonstrating sustained GH/IGF-1 elevation and preserved pulsatile secretion. The compound has clear pharmacological advantages over both native GHRH (too short-lived) and exogenous GH (bypasses pituitary regulation).[1][2]

Where it fits: GH-axis support for recovery continuity, body composition maintenance, and aging-related GH decline contexts. It is not a fast-acting transformation agent — value is typically judged by trend quality across multi-week blocks when fundamentals (sleep, training, nutrition) are stable.

For navigation, map this profile to Muscle Growth, Fat Loss & Recomp, Longevity / Healthy Aging, and Hormonal Support. Pressure-test with CJC-1295 vs Ipamorelin and CJC-1295 vs Sermorelin, and cross-reference with Tesamorelin for the FDA-approved GHRH analog comparison and GHRP-2 for an alternative secretagogue pathway.

FAQ

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile GH secretion from the anterior pituitary. In human studies, it produced sustained 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 increases lasting up to 6-11 days. It is one of the most studied GHRH analogs in the peptide research space.[1][2]

What does CJC-1295 peptide do?

CJC-1295 activates the GHRH receptor on pituitary somatotroph cells, triggering growth hormone synthesis and release while preserving natural pulsatile secretion patterns. The elevated GH drives hepatic IGF-1 production, which mediates downstream effects on recovery, body composition, and tissue repair.[1][2][3]

CJC-1295 with DAC vs without DAC: what is the practical difference?

The DAC (Drug Affinity Complex) enables covalent albumin binding, extending the half-life from ~30 minutes (no-DAC) to 5-8 days (with DAC). Both activate the same GHRH receptor. DAC provides sustained elevation with less frequent dosing; no-DAC provides sharper, shorter GH pulses. Neither is categorically superior — the choice depends on the research context.[1][4]

What are CJC-1295 benefits?

Documented benefits include sustained GH/IGF-1 elevation (2-10x GH, 1.5-3x IGF-1), preserved pulsatile secretion, extended duration of action, and potential support for recovery, body composition, and age-related GH decline. Downstream clinical benefits are supported by mechanism and class-level evidence but lack large-scale CJC-1295-specific outcome trials.[1][5][6]

What are CJC-1295 side effects?

Commonly reported side effects include injection site reactions, transient water retention, headache, flushing, and appetite changes. The Teichman study reported the compound was generally well tolerated. Glucose metabolism monitoring is appropriate with GH secretagogue use. Person-to-person variability is substantial.[1][5]

CJC-1295 dose and CJC-1295 dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Dose and dosage intent is valid, but this profile focuses on mechanism context, evidence quality, and risk-aware interpretation. Refer to primary research literature for protocol parameters.

CJC-1295 vs Ipamorelin: why compare them?

CJC-1295 works via the GHRH receptor; Ipamorelin works via the ghrelin receptor (GHS-R). They stimulate GH through distinct pathways, which is why their combination is frequently discussed. No combination clinical trial exists, but the pharmacological rationale for synergy is sound. See CJC-1295 vs Ipamorelin.[5]

CJC-1295 vs Sermorelin: what is the useful decision angle?

Both are GHRH analogs, but CJC-1295 has amino acid modifications that resist enzymatic degradation and (with DAC) albumin binding for extended half-life. Sermorelin uses the native GRF(1-29) sequence with a very short half-life. CJC-1295 offers longer duration; Sermorelin has a longer clinical history. See CJC-1295 vs Sermorelin.

Is CJC-1295 safe?

The Teichman human study reported CJC-1295 was generally well tolerated with mostly mild injection-site adverse events. Sigalos & Pastuszak’s 2018 review concluded GH secretagogues as a class have acceptable safety profiles, while noting the need for longer-term surveillance. Long-term safety data specific to CJC-1295 remains limited.[1][5]

What is the CJC-1295 half-life?

With DAC: approximately 5-8 days (due to albumin binding). Without DAC (Mod GRF 1-29): approximately 30 minutes. For comparison, native GHRH has a half-life under 10 minutes. The DAC version represents roughly a 500-fold increase in persistence over native GHRH.[1][4]

Where does CJC-1295 map inside site goal pathways?

Most commonly to Muscle Growth, Fat Loss & Recomp, Longevity / Healthy Aging, and Hormonal Support. Interpreted with a trend-first, fundamentals-dependent lens rather than acute-effect expectations.

Is CJC-1295 the same as Modified GRF 1-29?

Not exactly. Modified GRF 1-29 (Mod GRF 1-29) refers to CJC-1295 without DAC — it has the same amino acid modifications for DPP-IV resistance but lacks the Drug Affinity Complex for albumin binding. CJC-1295 with DAC and Mod GRF 1-29 share the same core sequence but differ in half-life and administration characteristics.[1][4]

References

1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683.
2. Ionescu M, Bhatt DL. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654.
3. Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19386527.
4. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PMID: 15817669.
5. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.
6. Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27(4):541-555. PMID: 24054930.
7. Merriam GR, et al. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14610297.
8. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a systematic review and meta-analysis. Obes Res Clin Pract. 2026;20(1):1-12. PMID: 41545261.
9. Merriam GR. Potential applications of GH secretagogs in the evaluation and treatment of the age-related decline in growth hormone secretion. Endocrine. 1997;7(1):49-52. PMID: 9449031.
10. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. PMID: 41476424.